Приказ основних података о документу
Purine nucleoside analogs in the therapy of cancer and neuroinflammation
dc.creator | Savić, Danijela | |
dc.creator | Stanković, Tijana | |
dc.creator | Lavrnja, Irena | |
dc.creator | Podolski-Renić, Ana | |
dc.creator | Banković, Jasna | |
dc.creator | Peković, Sanja | |
dc.creator | Stojiljković, Mirjana | |
dc.creator | Rakić, Ljubisav | |
dc.creator | Ruždijić, Sabera | |
dc.creator | Pešić, Milica | |
dc.date.accessioned | 2017-11-23T11:29:53Z | |
dc.date.available | 2900-01-01 | |
dc.date.issued | 2015 | |
dc.identifier.issn | 2300-3650 | |
dc.identifier.uri | http://www.degruyter.com/view/j/motth.2015.1.issue-1/motth-2015-0002/motth-2015-0002.xml | |
dc.identifier.uri | https://radar.ibiss.bg.ac.rs/handle/123456789/2633 | |
dc.description.abstract | Purine nucleoside analogs have been in clinical use for almost 50 years. At the beginning developed as antiviral agents, later their efficacy was demonstrated in cancer treatment, especially hematological malignances. The approval of new purine nucleoside analogs by US Food and Drug Administration (FDA) over the past decade implies that the interest for these drugs still exists. Here, we review new nucleoside analogs that are currently in preclinical or clinical development as anticancer agents. In addition, we highlight the potential for implementation of these drugs in other pathological conditions, particularly in neuroinflammation. | en |
dc.relation | info:eu-repo/grantAgreement/MESTD/Integrated and Interdisciplinary Research (IIR or III)/41014/RS// | |
dc.relation | info:eu-repo/grantAgreement/MESTD/Integrated and Interdisciplinary Research (IIR or III)/41031/RS// | |
dc.rights | openAccess | |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/4.0/ | |
dc.source | Molecular inhibitors in targeted therapy | |
dc.subject | Purine nucleoside analogs | |
dc.subject | Cancer | |
dc.subject | Neuroinflammation | |
dc.subject | Brain injury | |
dc.title | Purine nucleoside analogs in the therapy of cancer and neuroinflammation | en |
dc.type | review | |
dc.rights.license | BY-NC-ND | |
dcterms.abstract | Пешић, Милица; Станковић, Тијана; Савић, Данијела; Руждијић, Сабера; Лаврња, Ирена; Банковић, Јасна; Стојиљковић, Мирјана; Подолски-Ренић, Aна; Ракић, Љубисав; Пековић, Сања; | |
dc.rights.holder | © 2015 Danijela Savić et al. | |
dc.citation.issue | 1 | |
dc.citation.volume | 1 | |
dc.identifier.doi | 10.1515/motth-2015-0002 | |
dc.citation.apa | Savić, D., Stanković, T., Lavrnja, I., Podolski-Renić, A., Banković, J., Peković, S., Stojiljković, M., et al. (2015). Purine nucleoside analogs in the therapy of cancer and neuroinflammation. Molecular inhibitors in targeted therapy, 1(1), 3–14. | |
dc.citation.vancouver | Savić D, Stanković T, Lavrnja I, Podolski-Renić A, Banković J, Peković S, Stojiljković M, Rakić L, Ruždijić S, Pešić M. Purine nucleoside analogs in the therapy of cancer and neuroinflammation. Mol Inhib Target Ther. 2015;1(1):3–14. | |
dc.citation.spage | 3 | |
dc.citation.epage | 14 | |
dc.type.version | publishedVersion | en |
dc.identifier.fulltext | https://radar.ibiss.bg.ac.rs//bitstream/id/3396/MolInhibTargetTher_2015_1_1_3-14.pdf | |
dc.citation.rank | M13 |